Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer

Experimental and Molecular Pathology

Volumn 94, Issue 1, 2013, Pages 73-78

  Lin, Hong ^a,b   Huang, Jian Fei ^d   Qiu, Jin Rong ^b   Zhang, Hui Lin ^e   Tang, Xiao Jun ^b   Li, Hu ^b   Wang, Chang Jun ^c   Wang, Zhong Can ^c   Feng, Zhen Qing ^b   Zhu, Jin ^b,c  

^a Jiangsu Province Blood Center   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Huadong Medical Institute of Biotechniques   (China)

^d NANTONG UNIVERSITY   (China)

^e WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin D1; Immunohistochemistry; Invasive ductal breast cancer; Prognosis; TACSTD2

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION MOLECULES; CYCLIN D1; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84870953959     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.08.004     Document Type: Article

References (44)

1. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008, 113:2221s-2243s.
2. Baak J.P., Gudlaugsson E., Skaland I., Guo L.H., et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Research and Treatment 2009, 115:241-254.
3. Basu A., Goldenberg D.M., Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. International Journal of Cancer 1995, 9:472-479.
4. Bignotti E., Todeschini P., Calza S. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal of Cancer 2010, 46:944-953.
5. Calabrese G., Crescenzi C., Morizio E., et al. Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenetics and Cell Genetics 2001, 92:164-165.
6. Coughlin S.S., Ekwueme D.U. Breast cancer as a global health concern. Cancer Epidemiology 2009, 33:315-318.
7. Cubas R., Li M., Chen C., et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochimica et Biophysica Acta 2009, 1796:309-314.
8. Fang Y.J., Lu Z.H., Wang G.Q., et al. Elevated expressions of MMP7, TROP2, and surviving are associated with survival, disease recurrence, and liver metastasis of colon cancer. International Journal of Colorectal Disease 2009, 24:875-884.
9. Fantl V., Smith R., Brookes S., et al. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys 1993, 18:77-93.
10. Fattaneh A., Tavassoli F.A., Deville P. Pathology & Genetics of Tumors of the Breast and Female, Genital Organs (WHO of Tumor) 2003, IARC Press, Lyon.
11. Fernández Y., Cueva J., Palomo A.G., et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treatment Reviews 2010, 36:33-42.
12. Fong D., Spizzo G., Gostner J.M., et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Modern Pathology 2008, 21:186-191.
13. Fong D., Moser P., Krammel C., et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. British Journal of Cancer 2008, 99:1290-1295.
14. Fornaro M., Dell'Arciprete R., Stella M., et al. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. International Journal of Cancer 1995, 62:610-618.
15. Govindan S.V., Stein R., Qu Z., et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualising iodine radiolabel. Breast Cancer Research and Treatment 2004, 84:173-182.
16. Guerra E., Trerotola M., Dell' Arciprete R., et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Research 2008, 68:8113-8121.
17. Huang H., Groth J., Sossey-Alaoui K., et al. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clinical Cancer Research 2005, 11:4357-4364.
18. Khoury T., Sait S., Hwang H., et al. Delay to formalin fixation effect on breast biomarkers. Modern Pathology 2009, 22:1457-1467.
19. Kluger H.M., Kluger Y., Gilmore-Hebert M., et al. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Laboratory Investigation 2004, 84:320-331.
20. Lehn S., Tobin N.P., Berglund P., et al. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. The American Journal of Pathology 2010, 177:2886-2897.
21. Linnenbach A.J., Wojcierowski J., Wu S.A., et al. Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:27-31.
22. Linnenbach A.J., Seng B.A., Wu S., et al. Retroposition in a family of carcinoma-associated antigen genes. Molecular and Cellular Biology 1993, 13:1507-1515.
23. Lipinski M., Parks D.R., Rouse R.V., et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America 1981, 78:5147-5150.
24. McDougall A.R., Hooper S.B., Zahra V.A., et al. The oncogene Trop2 regulates fetal lung cell proliferation. American Journal of Physiology. Lung Cellular and Molecular Physiology 2011, 4:L478-L489.
25. Milacic V., Dou Q.P. The tumor proteasome as a novel target for gold (III) complexes: implications for breast cancer therapy. Coordination Chemistry Reviews 2009, 253:1649-1660.
26. Miotti S., Canevari S., Ménard S., et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. International Journal of Cancer 1987, 15:297-303.
27. Motokura T., Bloom T., Kim H.G., et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991, 350:512-515.
28. Mühlmann G., Spizzo G., Gostner J., et al. TROP2 expression as prognostic marker for gastric carcinoma. Journal of Clinical Pathology 2009, 62:152-158.
29. Nakashima K., Shimada H., Ochiai T., et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. International Journal of Cancer 2004, 112:1029-1035.
30. Ohmachi T., Tanaka F., Mimori K., et al. Clinical significance of TROP2 expression in colorectal cancer. Clinical Cancer Research 2006, 12:3057-3063.
31. Porter P. "Westernizing" women's risks? Breast cancer in lower-income countries. The New England Journal of Medicine 2008, 358:213-216.
32. Qiu J.R., Tang Q., Lin H., et al. Expression and clinical significance of Trop-2 in human pancreatic cancer. Zhonghua Yi Xue Za Zhi 2011, 91:103-106.
33. Ripani E., Sacchetti A., Corda D., et al. Human Trop-2 is a tumor-associated calcium signal transducer. International Journal of Cancer 1998, 76:671-676.
34. Schlotter C.M., Vogt U., Allgayer H., et al. Molecular targeted therapies for breast cancer treatment. Breast Cancer Research 2008, 10:211.
35. Shih L.B., Xuan H., Aninipot R., et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Research 1995, 55:5857s-5863s.
36. Sozo F., Wallace M.J., Zahra V.A., et al. Gene expression profiling during increased fetal lung expansion identifies genes likely to regulate development of the distal airways. Physiological Genomics 2006, 12:105-113.
37. Stein R., Basu A., Chen S., et al. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. International Journal of Cancer 1993, 55:938-946.
38. Taneja P., Maglic D., Kai F., et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clinical Medicine Insights: Oncology 2010, 4:15-34.
39. Tang Q., Liu Y.F., Zhu X.J., et al. Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. Human Pathology 2009, 40:300-305.
40. Terrinoni A., Dell'Arciprete R., Fornaro M., et al. The Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. Genes, Chromosomes & Cancer 2001, 31:209-220.
41. Trerptola M., Cantanelli P., Guerra E., Tripaldi R., et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogen 2012, 1-12.
42. Villablanca E.J., Renucci A., Sapède D., et al. Control of cell migration in the zebrafish lateral line: implication of the gene "tumour-associated calcium signal transducer," tacstd. Developmental Dynamics 2006, 235:1578-1588.
43. Wang J., Day R., Dong Y., et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Molecular Cancer Therapeutics 2008, 7:280-285.
44. Wu M., Liu L., Chan C. Identification of novel targets for breast cancer by exploring gene switches on a genome scale. BMC Genomics 2011, 12:547.